Loren Data's SAM Daily™

FBO DAILY ISSUE OF SEPTEMBER 04, 2004 FBO #1013
SOLICITATION NOTICE

B -- Validation of Methylation in a Promising Panel of Genes in Cervical Cancer, Precancer, and Normal Cervix Tissues and Cells

Notice Date

9/2/2004
 

Notice Type

Solicitation Notice
 

NAICS

541990 — All Other Professional, Scientific, and Technical Services
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
 

ZIP Code

20852
 

Solicitation Number

NCI-40166-NG
 

Response Due

9/16/2004
 

Archive Date

10/1/2004
 

Point of Contact

Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Renita Smith, Contract Specialist, Phone 301-496-8612, Fax 301-480-0241,
 

E-Mail Address

holdcram@exchange.nih.gov, rs442i@nih.gov
 

Description

The National Cancer Institute (NCI), Division of Cellular Epidemiology and Genetics (DCEG) plans to procure on a sole source basis services for Validation of methylation in a promising panel of genes in cervical cancer, precancer, and normal cervix tissues and cells with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75390. The services and supplies will be procured in accordance with the simplified acquisition procedures authorized by FAR Part 13. The North American Industry Classification System Code is 541990 and the business size standard is $6M. In 2004, NCI/DCEG performed methylation profiling of cervical cancer study using NotI-based restriction landmark genomic scanning (RLGS). RLGS was used to scan the human genome for methylated CpG islands, thus identifying methylated CpG islands that may reflect inactivation of TSGs. This effort identified several markers of possible utility in understanding the progression of HPV infection to neoplasia and in early detection of cervical precursors. Based on this work, we are currently working with investigators at the Roswell Park Cancer Institute (Buffalo, New York) to develop target-specific, optimized real-time PCR assays for three of the most promising markers (found methylated in the highest frequency among cervical cancers compared to controls). Validation by diagnosis and by specimen type will be conducted for these three markers in the following: (a) cervical cancers (n=15 archived frozen tissues), (b) CIN3 (n=20 liquid-based cytology specimens, (c) human papillomavirus (HPV) positive cytology specimens (n=50). Recently, researchers at UT Southwestern have published data using conventional methylation specific PCR assays indicating that the tumor necrosis factor decoy receptor DcR1 was methylated in 50 of 50 cervical cancers tested. Unpublished pilot data from this group has further demonstrated markers detectable in liquid-based clinical cervical cytology specimens and present in precursor lesions. In addition to the decoy receptor, four promising methylation markers have also been identified for identifying early cervical neoplasia (82-100%) by this group. Of particular interest are genes that are not typically methylated in low grade lesions that have been found to be methylated in precancer. However, optimized real-time PCR (RT PCR) assays for this panel developed at UT Southwestern have not been developed. The goal of the present work is to therefore, develop optimized RT PCR assays for the two decoy receptors as well as the additional promising markers and to subsequently use these assays to test the same set cervix tissues/cells (cancer, precancer, and normal) that will be tested in our on-going validation work based on RLGS results. The laboratory of Dr. Adi Gazdar at the University of Texas, Southwestern Medical Center is the only source known to the NCI that can develop the assays and further validate these unpublished markers in cervix specimens. This is not a request for competitive quotation. However, if any interested party believes it can perform the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other furnished information must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform this requirement. Capability statements must be received in the contracting office by 1:00 PM EST, September 16, 2004. If you have any questions they must be submitted in writing to Malinda Holdcraft, Purchasing Agent, at holdcram@exchange.nih.gov or by fax 301-402-4513. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Solicitation number must be cited on all correspondence, NCI-40166-NG.
 

Place of Performance

Address: Bethesda, MD

Zip Code: 20892

Country: USA
 

Record

SN00664069-W 20040904/040902211804 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |